Developer docs
API playgroundTry for free, no card

Search company profiles

Emboline

Full company profile

uuid000238o

Namestring
Emboline
Legal namestring
Emboline, Inc.
Websiteurl
emboline.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Emboline, Inc. is a privately held, venture-backed medical device company headquartered in Santa Cruz, California, developing the Emboliner® Full-Body Embolic Protection Catheter (EPC-03) for use during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is a transfemorally delivered, dual-layer Nitinol mesh filter with an integrated self-sealing access port, designed to capture embolic debris released into the bloodstream and provide protection to all three cerebral vessels as well as the kidneys and other organs — distinguishing it from cerebral-only protection devices such as Boston Scientific's Sentinel CPS. The company is led by founder/CTO Amir Belson, M.D. (a serial entrepreneur with prior exits to Intuitive Surgical, C.R. Bard, and Stryker) and CEO Scott Russell (a Nitinol technology veteran with prior leadership roles at Cordis/NDC). The leadership team has collectively authored more than 825 issued and pending patents.

Emboline has not yet commercialized its product; the Emboliner is investigational and labeled "not available for sale." In March 2026, the company reported positive results from its U.S. pivotal IDE trial (PROTECT H2H), a 522-patient head-to-head randomized study against Sentinel CPS, meeting all primary and secondary safety and efficacy endpoints with superior debris capture (93 vs. 31 particles ≥150µm), higher technical success (95.9% vs. 87.1%), and non-inferior 30-day MACCE (4.5% vs. 5.0%). The company has raised approximately $93 million across disclosed funding rounds, including a $55M Series D in May 2021 and a $20M growth capital round from Trinity Capital in March 2026.

The business model is hardware sales of a single-use disposable catheter to hospitals and interventional cardiology / structural heart programs performing TAVR. Commercial launch is planned in the United States (pending FDA PMA) and Europe (pending CE Mark) via direct hospital sales, supported by medical conference presence (ACC, TCT, PCR London Valves, euroPCR), peer-reviewed publications, and KOL relationships established through the clinical trial program. The company has 11-50 employees and was founded circa 2011-2014.

Short descriptiontext

Emboline is a private medical device company developing the Emboliner Full-Body Embolic Protection Catheter, a dual-layer Nitinol mesh filter designed to capture embolic debris during TAVR and other structural heart procedures, serving hospitals and interventional cardiology departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Cruz, United States
HQ citystring
Santa Cruz
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
embolic protection devices, transcatheter heart valve, TAVR cerebral protection, aortic embolic filters, interventional cardiology devices
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical and Medical Instrument Manufacturing339112
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Embolic Protection Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Emboline generates revenue through sale of the Emboliner Embolic Protection System, a disposable medical device used during TAVR procedures. The company is pre-commercial, preparing for launch following regulatory approval.

vcnewsdaily.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Emboliner
Description

Emboliner® Full-Body Embolic Protection System - the company's lead product designed to provide complete cerebral and systemic embolic protection during structural heart interventions such as TAVR.

emboline.com
Core offering1 text field

Emboline develops and manufactures the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a single-use, dual-layer Nitinol mesh filter catheter with an integrated self-sealing access port designed to capture and remove embolic debris released during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is deployed transfemorally into the aorta to provide comprehensive cerebral and systemic protection (brain, kidneys, and other organs) from ischemic complications. The company also offers the EPT-01 Angiographic Pigtail (130cm) as an accessory component.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 93 vs 31 particles captured (≥150µm) - superior debris capture vs Sentinel CPS
+3 more records
Product overview1 text field

Emboline offers a single unified product: the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a medical device consisting of a dual-layer Nitinol mesh filter with an integrated expanding access port. The device is deployed through the transfemoral puncture, positioned in the aorta to capture debris liberated during transcatheter aortic valve replacement (TAVR) and other structural heart procedures, protecting the brain, kidneys, and other organs. The product is investigational and not yet commercially available.

Product and service2 records
1Emboliner® Embolic Protection Catheter (EPC-03)
CategoryEmbolic Protection Devices
Description

A single-use, dual-layer cylindrical Nitinol mesh filter catheter with an integrated self-sealing expanding access port. The device is deployed transfemorally into the aorta during TAVR and other structural heart procedures to capture embolic debris (calcified valve tissue, thrombus, foreign material) released into the bloodstream, providing full-body protection covering all three cerebral vessels and the kidneys/other organs. Compatible with leading self-expanding and balloon-expandable TAVR systems.

2EPT-01 Angiographic Pigtail Catheter (130cm)
CategoryEmbolic Protection Devices — Accessories
Description

130cm angiographic pigtail catheter offered by Emboline as an accessory component compatible with the Emboliner Embolic Protection System for structural heart and TAVR procedures in both USA and EU markets.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1SWAT Medical AB
Strategic tierCoreTypeOthersAnnounced on2024-04-04
Description

Emboline acquired a significant embolic protection intellectual property portfolio from SWAT Medical AB, strengthening its IP position in the embolic protection technology space.

emboline.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston Scientific markets the Sentinel CPS, the only commercially established embolic protection device for TAVR and Emboline's direct head-to-head comparator in the PROTECT H2H pivotal trial. Both target the same structural heart / interventional cardiology customers with catheter-based embolic protection during TAVR.

2AorticLab S.r.l.
TypeDirect peer
Description

AorticLab is developing the FLOWer embolic protection device for TAVR and structural heart procedures in Europe, directly overlapping Emboline's product positioning. Emboline previously pursued patent infringement claims against AorticLab in the UPC, indicating direct competitive overlap.

TypeBroad incumbent
Description

Edwards is the market leader in transcatheter aortic valve replacement (SAPIEN platform) and a structural heart incumbent whose TAVR procedures drive demand for embolic protection adjuncts like Emboliner. Comparable because Emboline's device is used during Edwards' TAVR cases.

TypeBroad incumbent
Description

Medtronic is a leading TAVR provider (CoreValve/Evolut platform) and broad structural heart incumbent. Emboliner is designed to be compatible with leading TAVR systems including Medtronic's, making Medtronic a strategic customer and a broad incumbent in the same procedure ecosystem.

5Abbott
TypeBroad incumbent
Description

Abbott is a major structural heart player (Navitor, MitraClip, TriClip) and a TAVR competitor, providing a comparable addressable procedural base where embolic protection adjuncts like Emboliner could be deployed across both aortic and mitral transcatheter procedures.

TypeEmerging player
Description

Protembis is developing the ProtEmbo cerebral embolic protection system for TAVR, an emerging competitor with a similar indication and procedural workflow overlap. It is an early-stage European peer focused on the same embolic protection opportunity during structural heart interventions.

TypeEmerging player
Description

Contego Medical develops embolic protection and delivery technologies for endovascular procedures, with overlapping technology foundations (catheter-based filtration) and interventional cardiology/structural heart target customers.

TypeEmerging player
Description

InspireMD markets carotid and embolic protection devices (CGuard, MeshGuard) for endovascular procedures and is an emerging peer in embolic protection, sharing the same catheter-based mesh/filter technology approach for cerebral and systemic embolic risk mitigation.

TypeBroad incumbent
Description

Inari Medical specializes in catheter-based thrombectomy and venous/arterial embolic protection devices (FlowTriever, ClotTriever). While focused on venous thromboembolism, it shares the catheter-based embolic protection technology paradigm and interventional endovascular customer base.

TypeBroad incumbent
Description

Penumbra develops catheter-based thrombectomy and embolic protection systems (Indigo, Lightning). It is a broader incumbent in interventional catheter-based embolic/debris management, addressing similar clinical problems to Emboline's full-body embolic protection in different vascular territories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Emboline

Embolic Protection Medical Devicesemboline.com

Emboline is a private medical device company developing the Emboliner Full-Body Embolic Protection Catheter, a dual-layer Nitinol mesh filter designed to capture embolic debris during TAVR and other structural heart procedures, serving hospitals and interventional cardiology departments.

What Emboline does

Emboline, Inc. is a privately held, venture-backed medical device company headquartered in Santa Cruz, California, developing the Emboliner® Full-Body Embolic Protection Catheter (EPC-03) for use during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is a transfemorally delivered, dual-layer Nitinol mesh filter with an integrated self-sealing access port, designed to capture embolic debris released into the bloodstream and provide protection to all three cerebral vessels as well as the kidneys and other organs — distinguishing it from cerebral-only protection devices such as Boston Scientific's Sentinel CPS. The company is led by founder/CTO Amir Belson, M.D. (a serial entrepreneur with prior exits to Intuitive Surgical, C.R. Bard, and Stryker) and CEO Scott Russell (a Nitinol technology veteran with prior leadership roles at Cordis/NDC). The leadership team has collectively authored more than 825 issued and pending patents.

Emboline has not yet commercialized its product; the Emboliner is investigational and labeled "not available for sale." In March 2026, the company reported positive results from its U.S. pivotal IDE trial (PROTECT H2H), a 522-patient head-to-head randomized study against Sentinel CPS, meeting all primary and secondary safety and efficacy endpoints with superior debris capture (93 vs. 31 particles ≥150µm), higher technical success (95.9% vs. 87.1%), and non-inferior 30-day MACCE (4.5% vs. 5.0%). The company has raised approximately $93 million across disclosed funding rounds, including a $55M Series D in May 2021 and a $20M growth capital round from Trinity Capital in March 2026.

The business model is hardware sales of a single-use disposable catheter to hospitals and interventional cardiology / structural heart programs performing TAVR. Commercial launch is planned in the United States (pending FDA PMA) and Europe (pending CE Mark) via direct hospital sales, supported by medical conference presence (ACC, TCT, PCR London Valves, euroPCR), peer-reviewed publications, and KOL relationships established through the clinical trial program. The company has 11-50 employees and was founded circa 2011-2014.

Emboline firmographics

Firmographics
Name
Emboline
Legal name
Emboline, Inc.
Website
https://emboline.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Emboline is a private medical device company developing the Emboliner Full-Body Embolic Protection Catheter, a dual-layer Nitinol mesh filter designed to capture embolic debris during TAVR and other structural heart procedures, serving hospitals and interventional cardiology departments.
Ownership category
akta.pro rank

Emboline industry classification

Industry
Product category
Embolic Protection Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Embolic protection devices
  • Transcatheter heart valve
  • TAVR cerebral protection
  • Aortic embolic filters
  • Interventional cardiology devices

Where Emboline is headquartered

Location

Headquarters

HQ city
Santa Cruz
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Emboline business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales: Emboline generates revenue through sale of the Emboliner Embolic Protection System, a disposable medical device used during TAVR procedures. The company is pre-commercial, preparing for launch following regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Emboline product offering

Product offering

Core offering

Emboline develops and manufactures the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a single-use, dual-layer Nitinol mesh filter catheter with an integrated self-sealing access port designed to capture and remove embolic debris released during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is deployed transfemorally into the aorta to provide comprehensive cerebral and systemic protection (brain, kidneys, and other organs) from ischemic complications. The company also offers the EPT-01 Angiographic Pigtail (130cm) as an accessory component.

Product overview

Emboline offers a single unified product: the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a medical device consisting of a dual-layer Nitinol mesh filter with an integrated expanding access port. The device is deployed through the transfemoral puncture, positioned in the aorta to capture debris liberated during transcatheter aortic valve replacement (TAVR) and other structural heart procedures, protecting the brain, kidneys, and other organs. The product is investigational and not yet commercially available.

Differentiator

Problem solved

Functional benefit

Brands

  • Emboliner: Emboliner® Full-Body Embolic Protection System - the company's lead product designed to provide complete cerebral and systemic embolic protection during structural heart interventions such as TAVR.

Products and services

  • Emboliner® Embolic Protection Catheter (EPC-03) A single-use, dual-layer cylindrical Nitinol mesh filter catheter with an integrated self-sealing expanding access port. The device is deployed transfemorally into the aorta during TAVR and other structural heart procedures to capture embolic debris (calcified valve tissue, thrombus, foreign material) released into the bloodstream, providing full-body protection covering all three cerebral vessels and the kidneys/other organs. Compatible with leading self-expanding and balloon-expandable TAVR systems.
  • EPT-01 Angiographic Pigtail Catheter (130cm) 130cm angiographic pigtail catheter offered by Emboline as an accessory component compatible with the Emboliner Embolic Protection System for structural heart and TAVR procedures in both USA and EU markets.

Quantifiable outcome

  • 93 vs 31 particles captured (≥150µm) - superior debris capture vs Sentinel CPS
  • +3 more outcomes

Companies that use Emboline

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Emboline technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Emboline partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SWAT Medical ABcoreOthers · 4 April 2024Emboline acquired a significant embolic protection intellectual property portfolio from SWAT Medical AB, strengthening its IP position in the embolic protection technology space.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Emboline competitors and assessment

Company assessment

Direct peers

  • Boston Scientific: Boston Scientific markets the Sentinel CPS, the only commercially established embolic protection device for TAVR and Emboline's direct head-to-head comparator in the PROTECT H2H pivotal trial. Both target the same structural heart / interventional cardiology customers with catheter-based embolic protection during TAVR.
  • AorticLab S.r.l. AorticLab is developing the FLOWer embolic protection device for TAVR and structural heart procedures in Europe, directly overlapping Emboline's product positioning. Emboline previously pursued patent infringement claims against AorticLab in the UPC, indicating direct competitive overlap.

Broad incumbents

  • Edwards Lifesciences: Edwards is the market leader in transcatheter aortic valve replacement (SAPIEN platform) and a structural heart incumbent whose TAVR procedures drive demand for embolic protection adjuncts like Emboliner. Comparable because Emboline's device is used during Edwards' TAVR cases.
  • Medtronic: Medtronic is a leading TAVR provider (CoreValve/Evolut platform) and broad structural heart incumbent. Emboliner is designed to be compatible with leading TAVR systems including Medtronic's, making Medtronic a strategic customer and a broad incumbent in the same procedure ecosystem.
  • Abbott: Abbott is a major structural heart player (Navitor, MitraClip, TriClip) and a TAVR competitor, providing a comparable addressable procedural base where embolic protection adjuncts like Emboliner could be deployed across both aortic and mitral transcatheter procedures.
  • Inari Medical: Inari Medical specializes in catheter-based thrombectomy and venous/arterial embolic protection devices (FlowTriever, ClotTriever). While focused on venous thromboembolism, it shares the catheter-based embolic protection technology paradigm and interventional endovascular customer base.
  • Penumbra: Penumbra develops catheter-based thrombectomy and embolic protection systems (Indigo, Lightning). It is a broader incumbent in interventional catheter-based embolic/debris management, addressing similar clinical problems to Emboline's full-body embolic protection in different vascular territories.

Emerging players

  • Protembis GmbH: Protembis is developing the ProtEmbo cerebral embolic protection system for TAVR, an emerging competitor with a similar indication and procedural workflow overlap. It is an early-stage European peer focused on the same embolic protection opportunity during structural heart interventions.
  • Contego Medical: Contego Medical develops embolic protection and delivery technologies for endovascular procedures, with overlapping technology foundations (catheter-based filtration) and interventional cardiology/structural heart target customers.
  • InspireMD: InspireMD markets carotid and embolic protection devices (CGuard, MeshGuard) for endovascular procedures and is an emerging peer in embolic protection, sharing the same catheter-based mesh/filter technology approach for cerebral and systemic embolic risk mitigation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Emboline social profiles

Digital presence

Emboline financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Emboline leadership team

Management profile

Number of profiles

Profiles8 records

Emboline funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Emboline M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emboline

What does Emboline do?

Emboline develops and manufactures the Emboliner® Full-Body Embolic Protection Catheter (EPC-03), a single-use, dual-layer Nitinol mesh filter catheter with an integrated self-sealing access port designed to capture and remove embolic debris released during transcatheter aortic valve replacement (TAVR) and other structural heart procedures. The device is deployed transfemorally into the aorta to provide comprehensive cerebral and systemic protection (brain, kidneys, and other organs) from ischemic complications. The company also offers the EPT-01 Angiographic Pigtail (130cm) as an accessory component.

Is Emboline a public or private company?

Emboline is a private company. It is classified as venture growth investor backed and is currently operating.

When was Emboline founded?

Emboline was founded in 2014. It employs 11 to 50 people.

Where is Emboline based?

Emboline is headquartered in Santa Cruz, United States, in the North America region.

How does Emboline make money?

One revenue line is on record: medical Device Sales.

Who are Emboline's main competitors?

Direct peers on record are Boston Scientific and AorticLab S.r.l.. Broad incumbents are Edwards Lifesciences, Medtronic, Abbott, Inari Medical and Penumbra. Emerging players are Protembis GmbH, Contego Medical and InspireMD.

Does Emboline have an API?

No public API is recorded for Emboline.

What industry is Emboline in?

Emboline's product category is Embolic Protection Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkFirst US commercial procedures completed with Emboline’s Emboliner deviceEmboline completed the first US commercial procedures with its Emboliner embolic protection system during two transcatheter aortic valve implantation cases at New York-Presbyterian/Columbia. The device, cleared by the FDA in September 2026, captures debris to prevent migration to vital organs. Emboline will now initiate a controlled commercial rollout across selected US structural heart centers.YahooFirst US commercial procedures completed with Emboline’s deviceEmboline completed its first US commercial procedures with the Emboliner embolic protection system during transcatheter aortic valve implantation at New York-Presbyterian/Columbia University Irving Medical Center. The procedures followed FDA 510(k) clearance in September 2026, and Emboline is now initiating a controlled commercial rollout across selected US structural heart centers.Medical Device NetworkFDA grants 510(k) clearance to Emboliner system for TAVR proceduresThe FDA granted 510(k) clearance to Emboline's Emboliner embolic protection system for TAVR procedures. The system's dual-layer filter captured significantly more clinically relevant debris than the SENTINEL device in the PROTECT H2H IDE study. Emboline plans a phased US commercial launch later this year.BioSpaceEmboline Receives U.S. FDA 510(k) Clearance for Emboliner® Embolic Protection SystemEmboline received FDA 510(k) clearance for its Emboliner embolic protection system for TAVR procedures. The system uses a circumferential dual-layer filter to capture debris, and the PROTECT H2H study showed greater capture and highest technical success. A phased U.S. commercial launch is planned later this year.Medical Device and Diagnostic industryEmboline Gains Funding to Compete in Embolic Protection MarketEmboline secured $20 million in funding from Trinity Capital to support the commercial launch of its embolic protection system, which is designed to reduce stroke risk during transcatheter aortic valve replacement procedures. The Santa Cruz-based company plans to reveal late-breaking data from its IDE clinical trial at the American College of Cardiology conference later this month. This financing positions Emboline to compete in a market where rivals Claret Medical and Keystone Heart have already been acquired by larger entities.Medical Device and Diagnostic industryEmboline Advances Emboliner System in TrialEmboline presented positive results from its pivotal PROTECT H2H global clinical trial for the Emboliner Embolic Protection System at the American College of Cardiology’s Annual Scientific Session. The trial met all primary and secondary safety and efficacy endpoints, demonstrating statistical non-inferiority to the control device in safety while showing superior debris capture and technical success rates. These findings support Emboline's plan to submit data for regulatory approval as it advances toward commercialization.PR NewswireEmboline Prevails in German Utility Model Infringement Action Against AorticLabA German court ruled in favor of Emboline in a utility model infringement action against AorticLab, finding infringement of multiple claims. The Munich Regional Court ordered AorticLab to cease offering, marketing, importing, using, and possessing the infringing products in Germany, and to compensate Emboline for damages. The judgment is subject to appeal under German law.Cardiovascular BusinessNew stroke prevention device for TAVR holds its own in head-to-head battle with SentinelEmboliner, an embolic protection device from Emboline, demonstrated noninferiority to Boston Scientific’s Sentinel Cerebral Protection System in the ProtectH2H clinical trial for TAVR patients. The study, involving over 500 patients across the United States, Germany, and Brazil, showed that while both devices had comparable safety outcomes, Emboliner captured three times more debris and achieved a higher technical success rate.PR NewswireEmboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026Emboline, Inc. announced positive results from its pivotal PROTECT H2H global clinical trial evaluating the Emboliner® Embolic Protection System in patients undergoing transcatheter aortic valve replacement (TAVR), presented as a late-breaking trial at ACC 2026. The randomized IDE study enrolled 522 patients and met all primary and secondary safety and efficacy endpoints, demonstrating superior debris capture (93 vs. 31 particles ≥ 150µm; p < 0.0001) and significantly higher technical success (95.9% vs. 87.1%; p = 0.0005) compared to Boston Scientific's Sentinel CPS control device. With pivotal data now presented, Emboline is advancing toward regulatory submission and commercialization.PR NewswireEmboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026Emboline, Inc. announced positive results from its pivotal PROTECT H2H randomized IDE clinical trial evaluating the Emboliner® Embolic Protection System in 522 patients undergoing transcatheter aortic valve replacement (TAVR), with results presented as a late-breaking trial at ACC 2026. The study met all primary and secondary safety and efficacy endpoints, demonstrating statistical non-inferiority to Boston Scientific's Sentinel CPS control device (4.5% vs 5.0% MACCE; p=0.0004) while achieving superior debris capture (93 vs 31 particles ≥150µm; p<0.0001) and significantly higher technical success (95.9% vs 87.1%; p=0.0005). The company is now advancing toward regulatory submission and commercialization, positioning the Emboliner as a potential new standard for comprehensive cerebral and systemic embolic protection in structural heart procedures.